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STRUCTURE OF THE DISSERTATION 
An abstract of the study is first presented. Thereafter there are 3 parts to the dissertation. 
Part A is the protocol that outlines the justification for the study, the methods and analyses as 
well as the potential implications. 
Part B presents the findings of the literature review that was conducted. 
Part C concludes the dissertation in the format of a submission to the South African Medical 
Journal. The format of the journal author instructions require that Vancouver referencing be 
used. To maintain consistency between the Parts, the Vancouver referencing convention – and 
not Harvard - has been used. 
Part D includes the appended documents 
Appendix A – Consent / Assent Form 
Appendix B – Ethics Approval 
Appendix C – “Instructions to authors” as provided by the South African Medical Journal 
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ABSTRACT 
Background: Hearing loss is a global health burden affecting 360 million people.  The highest 
prevalence is in the Developing World where hearing screening programmes are scarce, and 
failure to address growing high-risk populations will result in new deaf communities.  In 
resource stretched communities such as these, new strategies to alleviate this burden are 
necessary.  Advances in technology have led to innovative mobile digital devices like 
smartphones and tablets with the potential to test hearing through audiometric applications.  
Given the recent upsurge of mobile technology in Africa, it is befitting to determine whether the 
implementation of science can translate to health service delivery. 
Objectives: To validate the Apple iPhone mobile device using the uHearTM application “app” as 
a possible hearing screening tool in the Developing World. 
Methods: This was a quasi-experimental study design. Participants were recruited from the ENT 
Clinic at Groote Schuur Hospital in Cape Town.  All participants had a formal audiogram, and 
then completed the iPhone uHearTM test in 3 different settings – the waiting room, a quiet room 
and a soundproof room.  “Earbud” headphones supplied with the device were used. 
Results: 25 patients were tested (50 ears in total).  Pure tone thresholds recorded with the iPhone 
in all 3 rooms were compared to a formal audiogram.  Data collected were analysed using kappa 
statistical analysis.  The iPhone was found to be a highly sensitive test for high frequency 
hearing loss (2000Hz, 4000Hz, 6000Hz) in quiet and soundproof rooms.  Kappa values showed 
“good” and “very good” correlation of the iPhone thresholds when compared to the formal 
audiogram in the above environments, and was statistically significant with p values <0.05.  The 
iPhone was moderately sensitive for low frequency hearing loss (250Hz, 500Hz, 1000Hz) in a 
soundproof room, but poor in quiet and waiting room settings. 
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Conclusion: The iPhone uHearTM test is highly sensitive for detecting high frequency hearing 
loss, making it well suited as a screening tool to detect presbycusis, and ototoxic hearing loss 
caused by HIV & TB therapy and chemotherapy.  Its portability and ease of use makes it 
opportune to use in Developing World communities that lack screening programmes. 
Key Words: hearing loss, Developing World, screening programmes, ototoxicity, presbycusis, 
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The global burden of hearing loss continues to affect millions of people around the world, with 
new estimates reaching 360 million people (1), and an increased prevalence in Developing World 
nations (2).  Furthermore, it is projected to be among the top ten causes of the global burden of 
disease in 2015 (3, 4, 5).  Estimates of the percentage of Americans suffering from hearing loss are 
likely to increase to between 20 and 25% by the year 2015 (3), a country with vast resources and 
established hearing screening programmes. One can only imagine the projected decline in health 
and economic development of developing nations with little to no resources for screening 
programmes unless dramatic measures are taken to address this problem. 
 
The impact of hearing loss includes the inability to communicate, a delay in language 
development, economic and educational disadvantage, stigmatisation and social isolation. While 
the value of early detection of hearing loss in infants is well established, the awareness of 
hearing loss in the elderly and other high-risk groups is much lower (3, 4, 5). 
 
In a survey of ENT services in Sub-Saharan Africa, Fagan et al reported a paucity of audiology 
services in all 18 countries surveyed.  South Africa had approximately 1 audiologist per 100 000 
people, with the remaining countries having less than 1 audiologist per 100 000 people (6).  In 
addition, Sub-Saharan Africa has one of the highest prevalence rates of hearing loss at 15.7%, 
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Hearing Screening Programmes  
Screening programmes are the most effective way to detect hearing loss, but do not replace 
formal pure tone audiometry - the gold standard of diagnostic hearing assessment.  They involve 
testing a community for hearing loss by trained audiologists or other health professionals, and 
then referring patients with suspected hearing loss for more sophisticated audiological testing, 
and for a medical opinion. Screening tests can identify hearing loss in the young population at an 
early age where early intervention by way of grommets or hearing-aids can be administered, 
thereby facilitating rehabilitation as early as possible.  In the elderly population, hearing loss is 
often undertreated and under-diagnosed, due to lack of awareness by the patient and health care 
professionals.  Screening tests available in the Developed World for the elderly permit earlier 
recognition of hearing loss and implementation of rehabilitative measures, and maintains their 
independent lifestyle (4, 5).  
 
Many methods of hearing screening have been developed over the years, like questionnaires and 
telephone-based programmes (5).  In addition, other methods like interactive internet-based 
screening programmes have brought hearing screening programmes into the digital world (7, 8).  A 
valid concern with many of these testing tools is the interference of background (environmental) 
noise, which affects the reliability of results obtained in non-conventional testing environments.  
Two drawbacks of questionnaires are poor respondents, and subjectively, no quantifiable degree 
of detected hearing loss, i.e. the outcome depends on perceived disability (5). Telephone 
audiometry is widely used in the United Kingdom and in the Netherlands, and has been 
established as “The National Hearing Test”.  This system too, has a number of recognized 
problems, the 2 main limiting factors being: 1) the wide range of telephones available on the 
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market and 2) the fact that signals are presented to one ear, rather than to both ears (diotic) as 
listening with two ears has an additional benefit of 1.4 dB.  It does, however, have a sensitivity 
and specificity of 0.91 and 0.93 respectively (5). 
 
Internet-based programmes are devised through collaborative efforts involving medical 
professionals and IT specialists.  In what was one of the earliest publications of this kind, Seren 
et al did not find a significant difference between a web-based hearing test and conventional 
audiometry; both provided the same audiometric results and mean thresholds varied by no more 
than 1.78dB.  However further audiometric investigation is necessary if hearing loss is suspected 
(7). Problems with internet-based programmes are often device or environment related.  Device 
issues include variable earphones, calibration of device and software to be used, and quality and 
speed of internet connectivity.  Background noise is almost always an issue often necessitating 
calibration of noise levels (7, 9, 10). 
 
Tele-audiometry is also a web-based screening programme (11, 12). Through a website, an 
audiologist remotely operates a portable audiometer to generate pure tone stimuli at various 
frequencies and volumes to a patient at a distant location.  If or when the patient hears a sound 
stimulus, he/she responds by pressing a button on the audiometer. This response is captured by 
the server and relayed back to the audiologist. The audiologist then analyses the data, and then 
relays the results back to the patient, often at a later stage. The system is reported to work in 
flexible configurations and to support hearing tests anytime and anywhere, as long as internet 
access is available (9, 10). The main drawback is that tele-audiometry requires internet access (11, 
12). 
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Apple uHearTM Test (Figures 1 & 2) 
With the advancement of technology and the accessibility and availability of mobile devices, 
especially smartphones, mp3 players and tablets, it is not unexpected that a hearing screening 
program has been developed for such devices.  One such software program (application), entitled 
uHearTM, was developed by Unitron, a Canadian hearing aid company in 2009.  It was released 
by Apple, and is available as a free download on iTunes, and can be installed as an application 
onto any Apple touch interface device, including the iPhone, iPad and iPod Touch.  Once 
downloaded, the uHearTM application does not require internet connectivity to operate.  
Using an iPhone, the uHearTM application is basic in design and user-friendly.  It is a self-
assessment test, with easy-to-perform commands that can be followed by any audiologically 
challenged individual.  The uHearTM application generates results immediately after testing.  
With no waiting period, patients do not have to be recalled for test results.  Africa has 
experienced an exponential growth in mobile technology related sales, especially cellular 
phones, with 1 in 5 users owning a smartphone (13).  Making use of hearing screening tools that 
utilize already available technology would be ideal in resource-stricken communities and would 
be an excellent way to merge science with health benefits at a predictably low cost.  
 
However, despite being so freely accessible, there are no published studies that report the 
accuracy of the uHearTM application as a hearing screening tool. 
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Figure 1: Initial screen view 
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AIMS 
1. To determine the accuracy of audiometric screening with the uHearTM software application 
using an iPhone mobile device 
2. To ascertain the technical feasibility and clinical utility of using the device 
3. To test whether it is an effective and efficient screening tool for patients in centres where no 
access to audiologically trained personnel and equipment is available 




Validation as a hearing screening tool will be done by assessing the accuracy of the iPhone 
(using the uHearTM application) to detect pure tone thresholds at low frequencies:  250Hz, 
500Hz, 1000Hz, and high frequencies: 2000Hz, 4000Hz and 6000Hz, when compared to pure 
tone thresholds from a formal audiogram at the same frequencies.  In addition, the usability of 
the device and the “application” will be assessed with regards to ease of use, speed, and 
applicability as a self-assessment device. 
 
METHODOLOGY 
• Study design: A prospective study 
• Study population 
o Patients with or without hearing loss will be recruited in the ENT Outpatients 
Department at Groote Schuur Hospital 
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o Otoscopic examination will be performed before pure tone testing to exclude active 
otorrhoea and wax impaction.  Infection control will be maintained during testing 
o Inclusion Criteria - Participants between the ages of 15 – 80 years 
o Exclusion Criteria 
! Patients with visual impairment, developmental or cognitive problems, 
otorrhoea or impacted wax 
! Patients who do not speak English but understand the process and steps to 
complete the program will not be excluded 
o Demographic information (age and gender) will be collected 
o All patients will have an audiogram done by a trained audiologist within 2 weeks of 
the iPhone testing 
• Test Instrument 
o A single iPhone device will be used.  The uHearTM software application will be 
downloaded from the iTunes website (for free).  Apple “ear bud” earphones supplied 
with the device will be used 
o The device emits pure tone sounds at the following decibel levels and frequencies: 
! 10-25 dB, 25-30dB, 40-55dB and 70-100dB 
! At 250Hz, 500Hz, 1000Hz, 2000Hz, 4000Hz, 6000Hz 
o Each patient will be tested in 3 settings - the waiting room, a quiet room and a 
soundproof room 
o Instructions to participants: Once the application is opened and the ear buds are 
inserted, connectivity is confirmed.  The participant will simply follow the only 
command.  “When the slightest of sound is heard, please tap the screen”. 
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o The test takes 6 minutes to complete 
• Conduct of iPhone test 
o The test will be supervised by an audiologist or the Primary Investigator 
o The test must be conducted in all 3 different settings: 1. Waiting room (where we 
anticipate background noise); 2. Quiet room and 3. Soundproof room (soundproof 
booth) 
o A OMD G45 71-6229 PsioTM sound level meter will be used at regular intervals to 
measure background noise (all 3 environments will be tested daily, and levels need to 
adhere to the South African Bureau of Standards (SABS) requirements for each 
environment 
o The Apple “earbud” earphones that are supplied with the device are inserted into the 
patient’s ear and the position of the ear bud is confirmed by the supervisor 
o The device is turned on, the uHearTM program is initiated, and the volume of speaker 
is calibrated before each test 
o The right ear is tested first, then the left ear in the waiting room, quiet room and the 
soundproof room 
o The iPhone device captures the responses and plots the results as an audiogram 
 
STATISTICAL ANALYSIS 
The primary outcome measures will be pure tone thresholds obtained by the iPhone device in all 
3 locations, and the formal audiogram pure tone thresholds. Data collected from the iPhone and 
uHearTM application will be analysed using Kappa statistical analysis.  This will describe how 
well the thresholds (hearing level in decibels) at a particular frequency correlate with the 
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thresholds (hearing level in decibels) at the same frequency as the gold standard – the formal 




The study will be approved by the Research Ethics Committee, Faculty of Health Science, 
University of Cape Town.  All participants will give informed consent, assent if underage. 
 
PILOT STUDY 
A small pilot study was first conducted in the Division of Otolaryngology at the University of 
Cape Town to determine whether the study was at all feasible. The accuracy of an audiometric 
test (uHearTM) using the iPod Touch was assessed and correlated with a formal audiogram.  Of 
40 patients recruited at the ENT clinic, 15 were tested in the waiting room, 25 were tested in the 
quiet room, and 10 (of the 25) were further tested in the soundproof room.  The data captured 
were then automatically plotted onto an audiogram, and results from the 3 different settings were 
correlated with the formal audiogram performed by a trained audiologist.  Accuracy of results 
was measured by the decibel discrepancy between formal audiogram and the iPod Touch 
audiograms.  Results showed that in the soundproof room, the decibel discrepancy was within 0-
7.5dB of the formal audiogram at both low and high frequencies with a sensitivity of 100 
percent.  In the quiet and waiting rooms, the decibel discrepancy increased to more than 10dB, 
and in 6 patients, to more than 20dB (12 percent).  However, at the high frequencies, the decibel 
discrepancy was much improved with a specificity approaching 70 percent.  The comparative 
results of the decibel discrepancy between the waiting room and the soundproof room 
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audiograms, were found to be statistically significant (p=0.0001).  We concluded that the study 
was feasible.   
 
RISKS TO PATIENTS 
There are no additional risks or expenses to the patients. 
 
POSSIBLE CONCLUSIONS 
An ideal screening program for the Developing World is one that is portable, quick and easy to 
use, safe and cost-effective and can be used in areas that otherwise would have no access to 
audiology testing without the expertise of a skilled audiologist. 
Should the Apple iPhone and uHearTM program prove to be technically feasible and clinically 
credible as a screening tool in our clinical setting of an ENT outpatients’ department, it might be 
concluded that it is suited for non-audiologically trained skilled health care workers as a 
community-based project to screen for hearing loss in high-risk populations that reside within the 
Developing World setting. 
 
DISCLAIMER 
The Division of Otorhinolaryngology and Groote Schuur Hospital do not have any affiliation to 
the Apple or Unitron companies. 
 
BUDGET 
The purchase of an iPhone mobile device is valued at R9500.00 
The OMD G45 71-6229 PsioTM sound level meter belongs to Groote Schuur Hospital. 
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OBJECTIVES 
The first objective was to identify the burden of disease for hearing loss globally, and to highlight 
its impact on individuals and their communities.  Specific emphasis was placed on the 
Developing World and Sub-Saharan Africa.  In addition, specific adult population groups were 
identified to be high risk – the elderly, who are prone to adult onset hearing loss (presbycusis) 
and patients receiving potentially ototoxic drugs - like chemotherapy; anti-TB therapy; HIV 
therapy). 
   
The second objective was to identify a way forward to address disabling hearing loss within 
resource-poor communities – reviewing screening programmes in general, and monitoring for 
any above-mentioned high-risk groups, as well as the effectiveness of different screening 
procedures that could work in low-budget settings.  Included in this was to highlight available 
technological advancements in audiometric applications (hearing assessment tools), and those 
that can be effectively utilised in Developing World communities. 
 
CONTEXT 
There is presently a global increase in the number of people with disabling hearing loss.  
Estimates have risen to 5.3% of the world’s population.  Notwithstanding the fact that hearing 
loss is multifactorial, affects all age groups, and extends beyond all geopolitical and 
socioeconomic barriers, the recent World Health Organisation (WHO) report on the Global 
Burden of Hearing Loss, highlights the overwhelming majority of sufferers as having a distinct 
population profile: adults with low incomes living in the Developing World including Sub-
Saharan Africa (1). Recognising high-risk groups within this larger population can help to identify 
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what is failing in existing services, and identify potential sustainable avenues to address this 
global problem. 
 
LITERATURE SEARCH STRATEGY AND QUALITY CRITERIA 
The information presented in this paper is supported by a Pubmed Medline search using the key 
words: hearing loss, deafness, hearing screening, mobile devices, developing world, ototoxicity, 
tuberculosis, TB, HIV, ARVs, presbycusis, age related hearing loss, technology, global health.  
Clinical studies and systematic reviews that directly address the above-mentioned population-
specific hearing loss, hearing screening tools and mobile device audiometry, were included.  
Four global statistics online sources were used - The World Health Organisation (WHO), the 
Health Professions Council of South Africa (HPCSA), the United Nations (UN) and up-to-date 
statistical factsheets from verifiable sources of industry. 
 
INCLUSION CRITERIA FOR ARTICLES WERE STUDIES RELATING TO:  
• The global burden of Hearing Loss in the Developing world – including prevalence and its 
impact on society and the individual 
• Adult populations at high risk of hearing loss, in particular high frequency hearing loss – 
specifically the elderly and drug-related hearing loss (ototoxicity). Examples of these include 
chemotherapy (anti-neoplastic drugs), second line anti-TB therapy and some anti-retroviral 
regimens 
• Available audiology services and hearing screening programmes in the Developing World 
• Non-conventional screening techniques 
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SUMMARY AND INTERPRETATION OF THE LITERATURE 
 
GLOBAL BURDEN OF DISEASE - EPIDEMIOLOGY 
The World Health Organisation (WHO) in 2012 estimated that 360 million people worldwide 
were living with disabling hearing loss* (1), an increase from their previous report in 2000 with an 
estimate of 278 million people (2).  The prevalence is greatest in South Asia, Asia Pacific and 
Sub-Saharan Africa, regions that fall within the Developing World.  With more than 50 percent 
of the world’s population residing here (3), addressing this challenge is an ethical one for human 
welfare, and a moral one for social justice. 
 
Funding for prevention, early detection, and rehabilitative programmes for hearing loss is 
severely limited in developing countries (3, 4).  Despite the reality of these needs being 
highlighted lately, advocates need to compete against “centre-stage” priorities like life-
threatening, pandemic communicable diseases such as Human Immunodeficiency Virus (HIV), 
Malaria, and Tuberculosis (5, 6). 
  
In addition, access to formal audiological testing is limited.  Africa has a paucity of audiologists 
in practice and training, with only a handful of screening programmes available (4).  Fagan et al, 
conducted a survey of ENT services in 18 African countries, and found that when compared to 
the UK service ratios, for the 18 countries as a whole, there was a deficiency of 20 406 
audiologists.  Also, South Africa’s access to audiology services, hearing aids and ENT care was 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
*	  Disabling hearing loss refers to hearing loss greater than 40 dB in the better hearing ear in adults (15 years or  
  older) and greater than 30 dB in the better hearing ear in children (0 to 14 years). 
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the most advantaged of the 18 African countries surveyed.  Currently there are 3457# registered 
health professionals in South Africa capable of screening for hearing loss - 3457 audiologists to 
service 50 million South Africans (7).  Not surprisingly then, South Africa still only fulfilled less 
than half of the required service ratios when compared to UK service ratios (4). 
 
THE IMPACT OF HEARING LOSS 
Adult hearing loss constitutes 91 percent of the 378 million sufferers (1).  One third of this group 
is over 65 years of age, indicating that the remaining two-thirds fall within the prime of 
economic life.  Hearing disability has far reaching effects, manifesting as lack of social and 
economic development as a community and a nation.  As an individual, consequences lead to 
social isolation, stigmatisation, and economic disadvantage (8, 9).  These adults tend to have much 
higher unemployment rates.  Those employed, are in lower grades of employment when 
compared to the general workforce (2, 5).  Additionally, an increase in prevalence of hearing loss 
is directly linked to a decrease in GNI (gross national income, per capita). 
 
HIGH-RISK POPULATION GROUPS IN THE DEVELOPING WORLD 
These are identified patients with the possibility of developing high frequency hearing loss, from 
certain aetiological factors. 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
#	  This figure is the total sum of 436 audiologists; 2940 speech therapists and audiologists and 81 community speech   
  and hearing workers.	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Human-Immunodeficiency Virus (HIV), Tuberculosis (TB) and related drug therapies 
As mentioned, in developing countries health provisions are dominated by communicable 
diseases like HIV and TB.  Non-communicable diseases like hearing impairment receive less 
attention, despite being a major public health concern.  In South Africa however, these diseases 
are linked, owing to the high prevalence of HIV and the increasing problem of multi-drug 
resistant (MDR) TB (within the pandemic of TB), together with existing socio-economic 
challenges (10-12).  
Sub-Saharan Africa houses 70.1% of all HIV positive individuals globally, a total of 25 million 
people (13,14) - the highest prevalence among people between 15 and 49 years of age (12).  
According to UNAIDS, there are approximately 15 million people receiving ARVs (14).  Hearing 
loss related to HIV is varied (Figure 3).  Sensorineural hearing loss (HFSNHL) can be caused by 
the virus itself neurotropically, or from ototoxic damage by ARVs (12, 15, 16, 17).  Nuceloside 
analogue reverse transcriptase inhibitors (NRTIs), one of the 3 classes of ARVS, is reported as 
most likely to cause SNHL (15).  Opportunistic infections can also target the auditory system, 
including many medications to treat them, and can have a synergistic effect on patients receiving 
ARVs (18). 
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Figure 3: Mechanisms of HIV-Related auditory disease (16) 
 
South Africa, like many sub-Saharan and South Asian countries, witnessed a dramatic upsurge of 
TB cases over the last decade (19). This still continues, due to HIV co-infection, and increased 
reports of multidrug-resistant TB (MDR-TB) nationally (20).  The prevalence of MDR-TB is five 
to six times higher than that in China and India (21, 22). 
Injectable aminoglycosides, the commonest drug by far to cause hearing impairment (23) are used 
to treat MDR-TB.  Treatment is guided by resistance to Isoniazid and Rifampicin (first-line 
therapy) (21).   Injectable aminoglycosides like Kanamycin and Amikacin are administered for 
prolonged periods of 18-24 months (22).  Harris & Fagan reported that SNHL occurred in 57 
percent of patients with MDR-TB after three months of aminoglycoside therapy and SNHL 
occurred in 70 percent of those who were also being treated for HIV (11).  The effect of the above 
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anti-TB regimen with ARVs had a synergistic ototoxic effect on the outer hair cells of the 
cochlea (12, 24).   
 
Anti-Neoplastic Therapy 
Cisplatin, a platinum compound, is a commonly used anti-neoplastic drug.  It’s ototoxic potential 
was first described by Piel et al almost 40 years ago (25).  Despite this, Cisplatin is widely used in 
standard treatment protocols for many cancers including soft tissue neoplasms, lymphomas, lung 
and head and neck squamous cell cancers (11, 26, 27).  Ototoxicity is a permanent, dose-related side-
effect, (25) with escalation of the dose causing almost every patient to develop some hearing loss 
(26).  Furthermore, noise exposure may result in a threefold increase risk of hearing loss (25) by 
acting synergistically with drugs that are not fully cleared from the cochlea (28).   
Cancer in the Developing World, referred to as ‘the cancer Tsunami’, is on the increase (29).  
According to Farmer et al, 70 percent of newly diagnosed cancers will be found in the 
Developing World by 2030.  Consequently, projected prevalence of ototoxicity-related hearing 
loss from chemotherapy protocols using platinum compound agents, like Cisplatin and 
Carboplatin, will increase immensely. 
 
The Elderly 
Presbycusis or age-related hearing loss, prevalent in the ageing population of the Developed 
World (30, 31), is also prevalent in the Developing World accounting for one third of adult hearing 
loss (1).  Patients and health care staff often don’t recognize hearing loss, particularly early on, 
making presbycusis under-diagnosed and undertreated (30-32).  
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Until recently, hearing loss in older adults was seen as an unfortunate and negligible part of 
ageing.  Presentation is classically gradual, leading to poor communication and inevitable social 
isolation.  Presbycusis is strongly associated with depression and cognitive decline (9, 30).  Recent 
studies show hearing loss to be independently associated with poor cognitive function and 
incident dementia when compared to same age individuals with normal hearing (33). 
 
SCREENING PROGRAMMES  
In general screening programmes are strategies intended to reduce morbidity and mortality of the 
disease process being tested.  They are designed to identify disease in their earliest stages when 
treatment is more successful.  Patients usually have no clinical symptoms. 
In order for screening programmes to be effective, the burden of disease must be significant 
enough to justify the effort of screening and an accurate, practical, and convenient screening test 
must exist - ideally one that has a good sensitivity (indicating few cases of the disease is missed) 
and an acceptable specificity (so that there are not too many false positives).  Since screening 
interventions are not designed to be diagnostic, appropriate follow-up is necessary for those with 
positive screening results to ensure effective treatment for the detected condition. 
 
SCREENING PROGRAMMES FOR HIGH-RISK GROUPS 
In the abovementioned high-risk groups, even without reported epidemiological data, the burden 
of disease is evident and hearing screening for these specific groups is suitable.  The concerns lie 
in 1) identifying a screening tool that is practical and highly sensitive, and 2) effective treatment 
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protocols for detected hearing loss, which as outlined above, is a resource-driven challenge.  As 
yet there are few programmes for any of the abovementioned high-risk groups in Sub-Saharan 
Africa.  Hearing screening if available, is done at the discretion of individual institutions and 
health care practitioners.  Failure to address these high-risk groups will lead to the creation of 
new deaf communities (3).   
The need to prioritize hearing screening for all HIV positive patients before commencement and 
during ARV therapy, is paramount.  Moreover, with improved health on ARVs, hearing loss may 
become a concerning symptom in quality of life assessments.  Baseline screening and follow-up 
hearing tests for chemotherapeutic drugs are deficient in South Africa and many developed 
nations, fundamentally hindering effective and comprehensive management of hearing 
difficulties for cancer patients (12, 24, 34). There are still few screening programmes for presbycusis 
in the Developed World (31).  Screening should be part of routine check-ups for the elderly, given 
individual lack of awareness, and gradual nature of progressive hearing loss (9). 
Ototoxicity monitoring 
Ototoxic monitoring encompasses 2 principles: 
• Firstly to screen, identify and monitor changes in the auditory system attributed to a drug
therapy.  These changes can be detected before they are even noticeable to the patient.
• Secondly, this is followed by prompt audiologic intervention, in addition to the consideration
of modifying the drug regimen.
These monitoring programmes are generally guided by audiologists, who decide on testing 
protocols; supervision of monitoring by personnel; and follow-up when clinically significant 
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hearing loss is detected.  All patients must have a baseline hearing test, used as the patient’s 
control, allowing for adequate interpretation of prospective tests (23, 35).   
Three main strategies for monitoring have emerged:  A) the basic audiologic assessment; B) high 
frequency audiometry (HFA); and C) otoacoustic emissions (OAE), each with their own 
considerations of utility (11).  Ideal practices should include all, yet this may not be always be 
possible.  According to the American Speech-Language-Hearing Association (ASHA) guidelines 
HFA has significant change criteria, and is well established with excellent specificity and 
sensitivity (11, 35).  Furthermore, HFA usually detects ototoxic changes prior to distorted product 
otoacoustic emissions (DPOAEs). 
In order to shorten test time while maintaining a high sensitivity for ototoxic damage, a 
shortened test protocol is recommended.  This targets monitoring a range of frequencies near 
each patient's upper frequency limit of hearing called the sensitive range of ototoxicity (SRO) 
and is identified on the baseline test prior to any drug therapy. The reported success rate for this 
protocol is approximately 90% in large groups of adult patients with ototoxic hearing changes 
observed using full-frequency.  The shortened test protocol therefore demonstrated a high degree 
of sensitivity to early decrements in hearing as a consequence of drug therapy, whether the SRO 
occurred within conventional audiometric frequencies (<8 kHz) or within the ultra-high 
frequency range (>8 kHz) (35). 
Prospective assessments of hearing function therefore remain the only reliable method to detect 
ototoxic damage prior to symptomatic hearing loss, relying solely on dosage or serum 
concentrations of ototoxic drugs is insufficient to predict the risk of ototoxicity (23).   
Monitoring hearing in patients receiving ototoxic drugs therefore provides audiologists 
opportunities to counsel patients about the effects of ototoxicity-induced hearing loss, tinnitus, 
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and vertigo, the synergistic effects of noise and ototoxic damage, and lastly communication 
strategies. 
 
Advances in Screening Tools 
Questionnaire and telephone-based hearing screening programmes are well utilised in first-world 
settings, but are unsuitable for developing world environments.  With the introduction of the 
digital age, through collaborative efforts between information technology and medicine, internet-
based programmes were born.  Audiologists could now test patients in remote locations.  
Drawbacks of early inventions related to hardware integration, software compatibility, 
environment interference, and specifically internet connectivity.  Recently tele-audiometry has 
shown promise in healthcare provision and professional education.  Testing is performed through 
application sharing software, allowing audiologists to remotely operate equipment on-site (36, 37).  
Tele-audiometry is performed synchronously (real-time testing with audiologist present remotely 
via videoconferencing), or asynchronously (automated testing with no audiologist present 
remotely).  It requires high-speed internet connectivity however, and if done synchronously, 
needs the availability of a local facilitator and an audiologist working remotely. Tele-audiometry 
also makes use of different audiometers; one such novel South African invention is the 
KUDUwave 500TM.   This portable audiometer comes with compatible software, testing for air 
and bone conduction.  It can also record environmental noise - vital information for pure tone 
testing outside soundproof booths.  A recent collaborative study done on older adults shows valid 
diagnostic pure tone thresholds and good test re-test reliability (38). 
With ever evolving technology available, and the accessibility of mobile devices like 
smartphones and tablets that use touchscreen interfaces, it is not unexpected to find hearing 
	  
33	  |	  P a g e 	  
	  
screening applications - “apps” available for download and use on these devices.  Many are 
quick and easy to use.  One such app is uHearTM, a software application devised for use on any 
Apple touch interface device. Marketed as a simple and easy tool, it doesn’t require specialised 
skills or internet access to perform once downloaded.  As this is a new field of interest that 
incorporates technology and medicine, there is very little in the literature, and only four 
published reports using Apple touch interface technology.  One study from Eastern Ontario 
Children’s hospital has tested a novel play audiometric “app”, designed in-house for addressing 
the shortcomings in play-audiometry testing (39).  Testing is in the first phase, with high 
sensitivity and specificity ratios reported.  In young children compliance for test completion is 
often a challenge, and threshold detection can be difficult and even lead to multiple visits for 
testing.  As this “app” for testing hearing is designed like a video game, showing promising 
results in improved compliance for test completion.  Further testing is underway.   
Sudzek et al was the first study to report hearing screening using the uHearTM “app” with an 
iPodTouch, and tested participants in a soundproof room and a clinic room (40).  Handel et al 
compared accuracy of threshold changes in patients with unilateral sudden sensorineural hearing 
loss (41), and Khosa-Shangase tested 100 South African school children in a school environment 
(42).  Outcome measures from all three studies involved comparing pure tone averages (PTAs) 
from the iPodTouch uHearTM test (from all test environments) to PTAs from a formal audiogram.  
Khosa-Shangase reported large deviations in the lower frequencies, standard deviations of 
>10dB at individual thresholds and a 34% higher pick-up rate of hearing loss (42).  The remaining 
two studies however, highlighted that it is possible to rule out moderate or worse (disabling) 
hearing loss (40, 41). In all three, even though low frequencies appeared inaccurately elevated (40-
42), one can possibly predict the degree of hearing loss in the abnormal hearing participant in the 
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high frequencies (40, 41).  Further, large multi-centre studies are still needed to challenge or 
corroborate these findings. 
 
THE WAY FORWARD 
1. Make more noise  
Current global health care efforts by the World Health Organisation (WHO) and the Prevention 
of Blindness and Deafness (PBD) campaign have created some awareness, but this is still not 
reaching the vast majority of people in need.  Addressing the global burden of hearing loss lies in 
addressing the inequities facing the distinct profiled population that is most affected, as much as 
it lies in addressing the sensory disability.  Global health policies and practices need to change 
and invest in sustainable solutions to address the global inequity between the developing and 
developed worlds. 
 
2. Devise adaptive hearing screening programmes suitable for Developing World systems that 
translate modern technology to health benefit 
Institution-based programmes are useful in communities with existing infrastructure and access 
to healthcare, but wont work in developing communities (37). 
Universal adult screening for hearing loss is not sustainable.  Prioritising high-risk groups is 
optimal.  A proposal to target community-related projects already in existence, like medical units 
that cater for high-risk groups, is the best way to start screening programmes.  Within these 
medical units, one needs to prioritise hearing loss with patients and healthcare workers, and 
facilitate regular hearing screening during visits.  Oncology centres, ARV rollout centres, TB 
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centres with inpatients receiving long-term therapies including “isolated MDR / X-MDR TB” 
sufferers, as well as community centres that are involved with directly observed therapy (DOTS).  
Ototoxic monitoring principles can be incorporated into regular visits.  Older adults who 
regularly receive chronic medication from satellite (community) clinics can also be recruited to 
have hearing screening tests performed while waiting for medication or during routine medical 
assessment of blood pressure, glucose etc.   
Community projects outside of medical visits but still within existing frameworks can also be a 
step-up for health-directed causes and can be targeted.  Introducing hearing screening in social 
spaces like schools, pension centres, places of worship, post-offices to name a few, are ideal 
places to identify undetected sufferers.  Testing is encouraged, but entirely voluntary.  
Community-based programmes are therefore ideal, as they can integrate into already existing 
services (36, 37).   
 
Screening techniques that reduce the need for skilled professionals, but at the same time are 
effective and safe, are needed because, as is already mentioned by Fagan et al, it would 
impossible to upgrade service delivery by only increasing the number of trained audiologists to 
meet the demand across Africa (4).  
There has been an exponential rise in the availability and usage of mobile phones and internet-
based technology in developing countries.  In addition, there are 5,98 billion mobile 
subscriptions globally (43, 44).  This includes South-East Asia, West Africa and Sub-Saharan 
Africa, with major controversy erupting on World Water Day 2013, when the United Nations 
highlighted that more people have access to mobile phones than working toilets (43).  Canadian 
marketing and social media consultant, Mike Kujawski reported that 1 in 5 people with mobile 
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phones in Africa owned a smartphone, and at least 8 African countries have mobile penetration 
rates of more than 100% (44).  Hence, advancement in technology fed the need to communicate.  
Herein lies an opportunity to leverage a technology that's already in use. 
With this in mind, a new age of hearing screening techniques can emerge - involving portable 
devices that require no expert audiologist (thereby reducing the demand on skilled audiologists), 
is quick, efficient, easy to perform, and uses already available tools to serve the needs of the 
people.  In this way, minimal resources are utilised, and screening is taken to the patient. 
 
IDENTIFICATION OF GAPS OR NEEDS FOR FURTHER RESEARCH 
• Large-scale epidemiological studies in the Developing World are needed, with emphasis on 
demographics including socioeconomic status, aetiology, risk factors. 
• Developing sustainable hearing screening programmes for high-risk population groups, 
including audiologist guided ototoxicity monitoring. 
• More collaborative studies are required to evaluate the feasibility of screening protocols 
using portable technology in low-budget countries, providing a great opportunity for “science 
implementation”. 
• More initiative is needed by governments and global health groups to improve health and 
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Hearing loss affects 360 million people globally.  The highest prevalence is in the Developing 
World where hearing screening programmes are scarce.  Failure to address high-risk populations 
will result in new deaf communities.  In resource-stretched communities, new strategies are 
needed.  Mobile devices like smartphones have the potential to test hearing through audiometric 
applications.  Given the upsurge of mobile technology in Africa, it is befitting to determine 
whether implementation of mobile applications can translate to this health problem. 
Objectives 
To evaluate the uHearTM “app” using an Apple iPhone mobile device as a possible hearing 
screening tool in the Developing World.  To also determine accuracy of certain hearing 
thresholds that could prove useful in early detection of hearing loss for high-risk populations in 
resource-poor communities. 
Methods 
This was a quasi-experimental study design. Participants were recruited from the Otolaryngology 
Clinic at Groote Schuur Hospital in Cape Town, South Africa.  All participants had a formal 
audiogram and completed the iPhone uHearTM test in 3 different settings – the waiting room, a 
quiet room and a soundproof room. “Earbud” headphones supplied with the device were used.  
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Results 
Twenty-five patients were tested (50 ears).  The iPhone uHearTM test was able to accurately 
detect moderate or worse hearing loss (PTA>40dB) with a sensitivity of 100% in all 3 
environments.  Specificity varied with 88% in the soundproof room, 73% in the quiet room and 
68% in the waiting room.  Using Kappa statistical analysis the iPhone was also found to be 
highly accurate in detecting high frequency hearing loss (2000Hz, 4000Hz, 6000Hz) in quiet and 
soundproof rooms.  Kappa values were “good” and “very good” at these frequencies, which were 
statistically significant (p <0.05).  The iPhone was moderately accurate for low frequency 
hearing loss (250Hz, 500Hz, 1000Hz) in a soundproof room, but poor in quiet or waiting rooms. 
Conclusion 
Using the iPhone, the uHearTM “app” is a feasible screening test to rule out significant hearing 
loss (PTA>40dB).  It is also highly sensitive for detecting threshold changes at high frequencies, 
making it reasonably well suited to detect presbycusis, and ototoxic hearing loss caused by HIV 
& TB therapy and chemotherapy.  Its portability and ease of use makes it opportune to use in 
Developing World communities that lack screening programmes. 
 
Key Words - hearing loss, developing world, screening tools, ototoxicity, presbycusis, mobile 
technology, portable audiology, HIV, TB, chemotherapy, ARVs, anti-TB therapy, global health 
 
DISCLAIMER 
The Division of Otorhinolaryngology, Groote Schuur Hospital and the authors do not have any 
affiliation to the Apple or Unitron companies. 
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INTRODUCTION 
Hearing disability is one of the major health problems affecting the world (1).  An estimated 360 
million people currently live with disabling hearing loss* (2).  Prevalence is greatest in the 
Developing World, where the majority of deaf people reside (1). Hearing loss is more common in 
adults, constituting 91% of all cases (2).  The highest prevalence rates are found in Sub-Saharan 
Africa (15.7 %) and South Asia (17%)  (1). Not dealing with this health challenge perpetuates 
economic and health decline, as is seen with the inverse relationship between the prevalence of 
hearing loss and GNI (2).  For the individual, hearing loss leads to poor communication and social 
isolation (3).  One is less likely to obtain employment, and for those who are employed, their 
income is in the lowest bracket (1, 3). 
Screening programmes directed at high-risk groups are necessary.  If effective, they can reduce 
morbidity from hearing loss through early detection and rehabilitation (4).  Highly sensitive tools 
that yield lower false positives and higher true negatives are ideal for screening and monitoring 
hearing.  Currently few screening programmes exist in the Developing World for high-risk 
groups.  Failure to do so, commits them to new deaf communities (5).  High-risk groups include 
the elderly, and patients who are receiving potentially ototoxic medication like chemotherapeutic 
agents (6), second line anti-tuberculosis (TB) regimens, and anti-retroviral therapy (ARVs) (1, 7, 8). 
These groups are at risk of developing high frequency hearing loss as explained below. 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
*	  Disabling hearing loss refers to hearing loss greater than 40 dB in the better hearing ear in adults (15 years or 
older) and greater than 30 dB in the better hearing ear in children (0 to 14 years). 
	  
	  




Presbycusis (adult-onset hearing loss) is generally under-diagnosed and undertreated.  This leads 
to late detection, disease progression, and poor rehabilitation (9, 10).  Hearing loss is 
predominantly high frequency and sensorineural.  Lin et al reported that older adults with 
hearing loss are more likely to develop cognitive impairment and dementia than their 
contemporaries without hearing loss (11, 12).  Regular monitoring and early detection and 
treatment of presbycusis could maintain an existing quality of life. 
 
HIV and TB therapy 
Currently 25 million people are HIV positive in South Africa (13).  Hearing loss can be caused by 
the HIV and / or the treatment thereof; both are implicated in sensorineural hearing loss (7).  
Treatment of opportunistic infections and anti-neoplastic therapy can have synergistic effects on 
patients receiving ARVs (7, 8).  TB therapy is one such treatment.  TB still continues to be an 
increasing problem in Sub-Saharan Africa due to the co-infection with HIV, with reports of 
increased cases of multidrug-resistant TB (MDR-TB) in South Africa (8, 14).  The treatment of 
which involves injectable aminoglycosides known to cause ototoxicity (8, 15).  This TB regimen 
has a synergistic ototoxic effect together with ARVs on the outer hair cells of the cochlea, 
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Chemotherapy 
Cancer rates are rapidly increasing in the Developing World (16).  Cisplatin, a commonly used 
anti-neoplastic drug, is known to cause irreversible dose-dependant ototoxicity (6, 17) leading to 
HFSNHL.  Noise exposure may result in a three-fold increased risk of hearing loss with Cisplatin 
(17, 18). 
 
Ototoxicity monitoring is aimed at preventing or minimizing the progression of hearing loss 
through prospective hearing assessments.  It is the most reliable method for detecting ototoxicity 
prior to development of symptomatic hearing loss (19).  It allows on to counsel patients, possibly 
modify treatment regimens, and rehabilitate hearing.  Three different methods of testing can be 
utilized namely: conventional audiology, high frequency audiometry (HFA) and otoacoustic 
emissions (OAEs).  HFA has significant change criteria and has excellent specificity and 
sensitivity (8, 19) but is generally not available in developing countries. 
 
Advances in Screening Techniques 
Screening programmes traditionally involve audiologists testing patients in soundproof booths.  
There has been an evolution of alternative screening programmes in recent years.  Telehealth 
projects allow patients in remote areas to be tested using high speed internet (20).  Portable 
audiometers are also advancing to provide good quality diagnostic audiometry in any 
environmental setting (21).   
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Global mobile phone penetration is at 85% of the world’s population (22) and 1 in 5 Africans own 
smartphones.  Automated hearing screening “apps” using commercially available technology 
present an opportunity to address the global problem of hearing loss.  Yeung et al from the 
Children’s Hospital of Eastern Ontario reported on the first portable clinical “conditioned play” 
iPad-based audiometer for the paediatric population (23). Their study shows promise in focusing 
on the shortcomings of existing play audiometry. The remaining papers have reported on the 
Apple uHearTM “app” using an iPodTouch device, with varying results.   uHearTM is a hearing 
program devised by Unitron and Apple for use on any touch-interface Apple device, and is freely 
available for download from the iTunes Apple store.  Sudzek et al was the first of three groups to 
evaluate this “app” as a potential hearing screening tool (24).  Using an iPodTouch, participants 
were tested in different noise level environments.  Pure tone averages (PTAs) calculated as a 
mean at thresholds of 500Hz, 1000Hz, 2000Hz & 4000Hz, from the uHearTM application were 
compared to the formal audiogram.  uHearTM was able to correctly diagnose the presence of 
moderate or worse hearing loss (PTA>40dB) in 100 participants, with a sensitivity of 98% and a 
specificity of 82% in the clinic.  In the soundproof room, sensitivity improved to 100%, and 
specificity improved to 90%.  Khoza-Shangase et al sampled a group of children using an 
iPodTouch in a school environment; PTAs (mean at thresholds of 500Hz, 1000Hz & 2000Hz) 
with compared to formal audiograms (25).  They reported large deviations in the lower 
frequencies, standard deviations of >10dB at individual thresholds and a 34% higher pick-up rate 
of hearing loss. The third study by Handzel et al tested participants with unilateral sudden 
sensorineural hearing loss using the uHearTM on an iPodTouch, and reported a sensitivity of 76% 
and a specificity of 91% when compared to a formal audiogram (26).  Inaccurately elevated 
thresholds at low frequencies using uHearTM were also detected, thereby corroborating the 
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findings of the previous study (25).  Interestingly, uHearTM reflected hearing thresholds more 
accurately in mid- to high frequencies compared to low ones, and deviations in low frequencies 
were less pronounced in the abnormal hearing (diseased) ear.  These two observations were also 
reported by Sudzek (24). These studies have highlighted two important points.  Firstly it is 
possible to rule out moderate or worse (disabling) hearing loss (24,26).  Secondly, even though low 
frequencies may be inaccurately elevated (24,25,26), one can possibly predict the degree of hearing 
loss in the abnormal hearing participant in the high frequencies (24,26).   
 
AIM 
To determine the accuracy of  
A) The iPhone using the uHearTM app as a screening tool for moderate or worse hearing loss 
(PTA >40dB), where PTA is the mean at thresholds of 500Hz, 1000Hz, 2000Hz & 4000Hz. 
B) Individual thresholds at certain frequencies, especially the high frequencies (may have use in 
high-risk population groups) 
 
METHOD 
The study was approved by the Research Ethics Committee, Faculty of Health Sciences, 
University of Cape Town.  The design was quasi-experimental.  Study participants were 
consecutively recruited from patients attending the Otolaryngology Clinic at Groote Schuur 
Hospital, Cape Town.  The inclusion criteria were patients from 15 to 80 years of age having had 
a formal audiogram by a trained audiologist at Groote Schuur Hospital in the previous 2 weeks.  
Exclusion criteria included otorrhoea; visual impairment; learning disability; and poor gross 
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motor skills rendering them incapable of tapping the screen.  Non-English speaking patients were 
not excluded if they understood the instructions after being explained the task.  All participants 
gave informed consent - assent if underage.  The results obtained from the iPhone testing did not 
affect the treatment plans of participants. 
 
Test Instruments 
An iPhone 4 mobile device (iOS 4.2) was used.  The uHearTM “app” was downloaded from 
iTunes onto the device at no cost.  The application allows users to test their pure tone air-
conduction hearing sensitivity as well as speech in noise.  For this study, participants only 
completed the hearing sensitivity test which employs a 267ms pulse duration, with a “10 dB 
down and 5 dB up” approach.  The time delay between tone presentations is randomized to 
prevent anticipation and the lowest threshold with two positive responses of three excursions is 
recorded as the hearing sensitivity.   
“Earbud” earphones that come standard with the device were used. With reference to calibration, 
a single iPhone was used to test all participants.  The same uHearTM application (version 1.0) was 
used for all participants tested. Ambient noise levels in all 3 test environments were measured at 
regular intervals with the OMD G45 71-6229 PsioTM	  sound level meter, providing an adequate 
measure of quality control.  Sound levels for the respective environment complied with the South 
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Technique 
Otoscopic examination was performed to exclude otorrhoea and wax impaction.  Infection 
control was maintained during testing. All participants had formal audiograms done, and were 
tested in 3 different settings with the iPhone, i.e. the waiting room (WR); a quiet room (QR) and 
the soundproof room (SR). 
 
Instructions to participants 
Participants were given the device and the earphones to insert.  The uHearTM “app” was selected, 
earphone connectivity confirmed and the participant was advised to “tap the screen when a sound 
is heard”.  The program plays a series of pure tones of varying levels so that a threshold can be 
determined.  On hearing a sound, the participant was expected to follow the commands.  The 
duration of the test is 6 minutes. No audiologist is normally required as this is a self-assessment 




For hearing screening, the presence or absence of moderate or worse hearing loss (PTA>40dB) 
in each ear was determined by formal audiometry, as 40dB is considered the critical hearing 
threshold for disabling hearing loss according to the WHO, and warrants further investigation. 
The iPhone uHearTM PTAs in all 3 settings were compared to the formal audiogram PTAs, where 
the PTA is calculated as a mean of thresholds (hearing in decibels) at 500Hz, 1000Hz, 2000Hz & 
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4000Hz.  This data was captured into 2x2 tables to calculate sensitivity, specificity and accuracy 
ratios. 
Additionally, in view of the possibility for agreement by ‘chance’, kappa analysis was performed 
on iPhone thresholds from all 3 settings when compared to the formal audiogram to detect 
agreement at all 6 frequencies.  Kappa values range from less than 0.2 to 1.0 depending on how 
well two thresholds correlate with each other, at a particular frequency.  The best correlation 
kappa value i.e. “very good” is one that is closest to 1.   This describes how well the thresholds at 
a particular frequency correlated with the thresholds at the same frequency of the gold standard – 
the formal audiogram, and values this correlation according to the range, described in Table 1. 
 
Kappa Values ‘Agreement’ / comparison 
< 0.2 POOR 
0.21 – 0.4 FAIR 
0.41 – 0.6 MODERATE 
0.61 – 0.8 GOOD 
0.81 – 1.0 VERY GOOD 
Table 1: Kappa range of values and their correlation 
 
RESULTS 
Thirty patients met the inclusion criteria and were recruited, of which 5 were excluded for 
incomplete testing (unrelated to device or software).  Twenty-five patients were therefore fully 
tested (50 ears in total).  Participants’ demographics are described in Table 2.   
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Total number of participants 25 
	  





15 – 86 


















Number of ears with PTA (dB) 50 
Normal  
Mild loss  
Moderate loss  
Moderate-Severe loss  
Severe loss  
Profound loss 	  














Table 2: Participants’ Demographics and Hearing Loss (as graded by the American Speech 
Language & Hearing Association’s (ASHA) Degree of severity of hearing loss) 
 
Accuracy of the iPhone uHearTM as a screening test:  All ears with moderate or worse hearing 
loss (PTA >40dB) were detected in all 3 settings.  This translated to a sensitivity of 100%.  Of 
the 42 ears without moderate or worse hearing loss (PTA ≤ 40dB), 15 had moderate or worse 
hearing in the waiting room (specificity of 64%); 11 had moderate or worse hearing in the quiet 
room (specificity of 74%); and 5 had moderate or worse hearing loss in the soundproof room 
(specificity of 88%) (Table 3).  Accuracy in the waiting room was calculated as 70%; the quiet 
room as 78% and the soundproof room as 90%.  
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Accuracy of the iPhone uHearTM thresholds at all 6 frequencies:  Kappa analysis compared the 
“agreement” of the iPhone thresholds in all 3 rooms to the formal audiogram thresholds as 
reflected in Table 4.  The iPhone was highly accurate at the high frequencies (2000Hz, 4000Hz, 
6000Hz), where there was “good” and “very good” correlation in the soundproof and quiet 
rooms (Table 4).  This was found to be statistically significant (p values <0.05).  The iPhone did 
not correlate well at low frequencies in all 3 rooms, being “fair to moderate” in the soundproof 
room, and “poor to moderate” in the quiet room.  The waiting room showed “poor to fair” 
correlation at low frequencies, and “moderate” correlation at high frequencies.  
 
 
 (Formal Audiogram) 




PTA ≤ 40dB 








PTA ≤ 40dB 








PTA ≤ 40dB 






Table 3: Accuracy of the iPhone in all 3 settings as a screening test compared to the formal 
audiogram 
 
The iPhone uHearTM therefore reflected thresholds more accurately in the mid to high 
frequencies than the low frequencies.  Furthermore, the soundproof room did not eliminate this 
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LOW	  FREQUENCIES	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Formal	  Audiogram	  
iPWR	   250	   500	   1000	  
250	   -­‐	  0.0516	   0.2217	   0.4123	  
500	   0.0044	   0.2399	   0.4997	  
1000	   -­‐	  0.0693	   0.2526	   0.5126	  
	   	   	   	  iPQR	   250	   500	   1000	  
250	   -­‐	  0.0101	   0.2751	   0.5677	  
500	   0.0134	   0.3102	   0.5113	  
1000	   -­‐	  0.0239	   0.212	   0.5207	  
	   	   	   	  iPSR	   250	   500	   1000	  
250	   0.097	   0.5309	   0.4386	  
500	   0.1309	   0.5283	   0.5316	  
1000	   0.0113	   0.481	   0.66	  (p=0.000)	  
	  
	  
HIGH	  FREQUENCIES	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Formal	  Audiogram	  
iPWR	   2000	   4000	   6000	  
2000	   0.496	   0.663	   0.4261	  
4000	   0.4667	   0.339	   0.5529	  
6000	   0.484	   0.187	   0.517	  
	   	   	   	  iPQR	   2000	   4000	   6000	  
2000	   0.73	  (p=0.001)	   0.5122	   0.5535	  
4000	   0.4471	   0.74(p=0.0000)	   0.69	  (p=0.0051)	  
6000	   0.4339	   0.69	  (p=0.0092)	   0.79	  	  (p=0.0026)	  
	   	   	   	  iPSR	   2000	   4000	   6000	  
2000	   0.75	  (p=0.000)	   0.72	  (p=0.0039)	   0.69	  (p=0.005)	  
4000	   0.73	  (p=0.000)	   0.85	  (p=0.000)	   0.89	  (p=0.000)	  
6000	   0.77(p=0.0007	   0.92	  (p=0.0010)	   0.94	  (p=0.000)	  
 
Table 4: Kappa values seen with iPhone thresholds all 3 rooms (waiting iPWR; quiet 
iPQR; soundproof iPSR) down the columns & formal audiogram thresholds across the 
rows.  The first table shows the low frequencies, and the second table shows the high 
frequencies.  In the “good” and “very good” correlation values, p values of <0.05 imply 
good statistical significance (figures in brackets). 
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DISCUSSION 
This study is one of the first to evaluate smartphone-assisted audiometry as a hearing screening 
tool for populations that currently have no access to formal audiometry.  Results indicate that the 
iPhone uHearTM application is reasonably accurate at screening for moderate or worse (disabling) 
hearing loss.  We found a sensitivity of 100%, with a very high negative predictive value, 
implying an ideal test for screening.  The highest test accuracy (90%) was found in a soundproof 
room with a specificity of 88%, rendering the least false positives.  This highlights caution when 
testing in a waiting room setting. 
The iPhone uHearTM application was found to be highly accurate for detecting high frequency 
hearing loss in quiet and soundproof rooms in patients with different levels of hearing.  The 
iPhone uHearTM application could therefore be used to screen those at high risk of developing 
high frequency hearing loss through early detection of abnormal or worsening thresholds. 
The iPhone uHearTM application therefore makes for an appropriate screening tool for disabling 
hearing loss, and to detect high frequency hearing loss that is seen with the abovementioned 
high-risk groups within poorly-resourced communities that have no access to health care.  In 
particular, it can be used to screen and monitor hearing in drug-related ototoxicity where high 
frequency assessments of both conventional audiometry and HFA have a high degree of 
sensitivity to detect early change in hearing (19).  
 
In addition, uHearTM is a self-assessment application that is freely available from iTunes for all 
Apple users and is downloadable to any Apple device with a touchscreen interface and speakers 
(includes iPhone, iPad and iPodTouch).  The test is quick and easy to perform, designed for use 
by people of any language, socio-economic status and intellectual capacity.  Patients who are 
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bed-bound, isolated, or too weak to ambulate to an audiology centre could benefit from a mobile, 
freely available self-assessment hearing screening test as this. 
 
POSSIBLE LIMITATIONS OF THE STUDY AND TECHNIQUE 
More participants with varying degrees of hearing loss would possibly yield more accurate 
positive and negative predictive values thereby rendering the testing more accurate. 
Environmental noise may have been a cause for poor results at the lower frequencies.  Testing 
can possibly be improved by using background noise eliminators.   Inset earphones are 
theoretically recommended as a more effective way to reduce ambient noise.  By being placed 
within the external ear canal, they can provide 30 to 40dB attenuation of ambient noise (27). In 
our study inaccuracy can be related to insertion depth, since “earbud” earphones sit just beyond 
the concha at the entrance to the external ear canal, which could explain the poor low frequency 
outcomes.  In the future, testing that incorporates inset earphones cupped by circumaural ear 
covers with integrated ambient noise level monitoring that eliminates or adjusts testing to 
accommodate background noise, can be done.  Although this would be ideal it does counter the 
intention to screen using a device with its standard hardware. A single iPhone device was used 




The sensitivity of the uHearTM  “app” used with the iPhone is adequate to screen for disabling 
hearing loss, and has good accuracy to high frequency hearing loss in soundproof and quiet 
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rooms.  Early detection of hearing loss with hearing screening programmes is thus possible using 
mobile digital technology.  A mobile, non-operator dependent method used to screen for 
disabling hearing loss and detect early high frequency threshold changes such as an Apple 
iPhone, can help overcome the lack of trained audiologists or available infrastructure in 
developing countries (5).  Because of its portability, hearing screening with the iPhone uHearTM 
test is taken directly to the patient and is an opportune way to utilise existing community health 
and educational facilities.    Oncology units, ARV rollout centres and TB hospitals with MDR / 
X-MDR TB sufferers are ideal centres to use this technology.  In addition, satellite clinics that 
regularly administer chronic medication for older adults can also be considered. 
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APPENDIX A: CONSENT FORM TO ACT AS A SUBJECT IN A CLINICAL STUDY 
TITLE:   Hearing Loss: Devising a screening tool using the iPhone mobile device 
 
INVESTIGATORS: 
Dr S Peer, Ms S Pithey, Prof JJ Fagan 
 
ADDRESS FOR ALL INVESTIGATORS: 
Division of Otorhinolaryngology, H53, OMB, Groote Schuur Hospital, Observatory, Cape Town, 7925 
 
DESCRIPTION: 
You are being asked to participate in this study to see whether the hearing test on the iPhone is accurate. 
We ask that you have the following tests done:  
1. Hearing test (audiogram) by a trained audiologist 
2. Hearing screening tests using the iPhone in 3 different settings namely; a soundproof room, a 
quiet room and a waiting room. 
 
RISKS AND BENEFITS: 
There are no risks or benefits to you, and the information collected from the iPhone will not be utilised in 
your hospital management plan.  It is for research purposes. 
 
COSTS AND PAYMENTS: 
There will be no additional costs to you or your family. 
 
CONFIDENTIALITY: 
The information obtained from this study will be published in the future such that your identity will 
remain anonymous.  Medical records related to this study are confidential, but may be examined by 
researchers from this institution.   
 
RIGHT TO WITHDRAW: 
You have the right to refuse to participate in this study at any time, and your decision will not adversely 
affect your care at this institution. 
 
VOLUNTARY CONSENT: 
I understand what is stated above and agree to participate in this clinical study. 
 
Participant Signature…..………………………..……..Guardian’s Signature...…………...………………. 
I certify that I have explained to the above individual the nature and purpose, the potential benefits, and 
possible risks associated with participating in this research study, have answered any questions that have 
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APPENDIX C: SAMJ AUTHOR GUIDELINES 
COPYRIGHT 
Material submitted for publication in the South African Medical Journal (SAMJ) is accepted 
provided it has not been published elsewhere. The SAMJ reserves copyright of the material 
published. 
The SAMJ does not hold itself responsible for statements made by the authors. 
AUTHORSHIP 
All named authors must give consent to publication. Authorship should be based only on 
substantial contribution to: (i) conception, design, analysis and interpretation of data; (ii) drafting 
the article or revising it critically for important intellectual content; (iii) final approval of the 
version to be published. All three of these conditions must be met (Uniform requirements for 
manuscripts submitted to biomedical journals; www.icmje.org/index.html). 
RESEARCH ETHICS COMMITTEE APPROVAL 
Evidence must be provided of Research Ethics Committee approval of the research where 
relevant. 
CONFLICT OF INTEREST 
Authors must declare all sources of support for the research and any association with the product 
or subject that may constitute conflict of interest. 
PROTECTION OF PATIENT'S RIGHTS TO PRIVACY 
Identifying information should not be published in written descriptions, photographs, and 
pedigrees unless the information is essential for scientific purposes and the patient (or parent or 
guardian) gives informed written consent for publication. Informed consent for this purpose 
requires that the patient be shown the manuscript to be published. (www.icmje.org) 
ETHNIC CLASSIFICATION 
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Short items are more likely to appeal to our readers and therefore to be accepted for publication.  
Original articles of 3 000 words or less, with up to 6 tables or illustrations, should normally 
report observations or research of relevance to clinical medicine. References should preferably 
be limited to no more than 15. 
Short reports/scientific letters, which include case reports (the SAMJ is rarely able to publish 
case reports), side effects of drugs and brief or negative research findings should preferably be 
1500 words or less, with 1 table or illustration and no more than 6 references. 
Editorials, Opinions, Issues in Medicine, etc. should be about 1000 words and are welcome, but 
unless invited, will be subjected to the SAMJ peer review process. 
Review articles are rarely accepted unless invited. 
Letters to the editor, if intended for the correspondence column, should be no longer than 400 
words with only one illustration or table. 
Obituaries should not exceed 400 words and may be accompanied by a photograph. 
MANUSCRIPT PREPARATION 
Research articles should have a structured abstract not exceeding 250 words comprising: 
Objectives, Methods, Outcome measures, Results and Conclusions. For scientific letters/short 
reports an abstract (summary) up to 100 words in length should be provided. 
Refer to articles in recent issues for guidance on the presentation of headings and subheadings.  
Abbreviations should be spelt out when first used in the text and thereafter used consistently.  
Scientific measurements should be expressed in SI units except: blood pressure should be given 
in mmHg and haemoglobin values in g/dl.  
If in doubt, refer to 'uniform requirements' above. 
ILLUSTRATIONS 
Figures consist of all material that cannot be set in type, such as photographs and line drawings. 
If any tables or illustrations submitted have been published elsewhere, the author should obtain 
written consent to republication from the copyright holder and the author(s). All illustrations, 
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figures etc. must be of high resolution/quality, preferably jpeg or equivalent but not powerpoint, 
and preferably attached as supplementary files. 
REFERENCES 
References should be inserted in the text as superior numbers and should be listed at the end of 
the article in numerical and not in alphabetical order. 
Authors are responsible for verifying references from the original sources. 
References should be set out in the Vancouver style and approved abbreviations of journal titles 
used; consult the List of Journals in Index Medicus for these details. 
Names and initials of all authors should be given unless there are more than six, in which case 
the first three names should be given followed by et al. First and last page numbers should be 
given. 
Journal references should appear thus: 
Price NC . Importance of asking about glaucoma. BMJ 1983; 286: 349-350. 
Book references should be set out as follows: 
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